CEO Change at dSPACE: Dr. Carsten Hoff Succeeds Martin Goetzeler
25.1.2023 17:54:00 EET | Business Wire | Press release
On April 17, 2023, Dr. Carsten Hoff (49) will become the new CEO of the dSPACE group succeeding Martin Goetzeler (60), who is leaving his post at his own request and for personal reasons. To ensure a smooth handover, Martin Goetzeler will continue to be available to the new CEO in an advisory capacity after April 17, 2023.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230125005072/en/
From left to right, dSPACE founder and shareholder Dr. Herbert Hanselmann, Dr. Carsten Hoff and Martin Goetzeler. (Photo: Business Wire)
Dr. Carsten Hoff is a highly experienced manager, who is ideally suited to the tasks ahead at dSPACE. He comes from a research and development-centric background with a degree in electrical engineering and a doctorate in computer science. He has international management experience and is familiar with dSPACE and the company's products.
Dr. Carsten Hoff is currently Managing Director of CLAAS E-Systems. Prior to that, he worked in various management positions at the automotive supplier HELLA. He will use his extensive experience from previous positions to provide strategic impetus for dSPACE and to continue to drive forward the new topics of software-based simulation and validation.
"I am very pleased to be joining the dSPACE company. I am very impressed by the company's development and dSPACE's role in the automotive industry. The values that the family-owned company dSPACE stands for convinced me,” stated Dr. Carsten Hoff.
"Dr. Carsten Hoff, an internationally experienced and technically skilled manager who is very familiar with the current challenges in our target markets is taking the helm – I wish him a good start in the company and with our customers," said Dr. Herbert Hanselmann, founder and shareholder of dSPACE.
"Under Martin Goetzeler's successful leadership, dSPACE has sustainably strengthened its market position by setting a decisive course in terms of consistent portfolio expansion, globalization, and future-oriented structures. By continually expanding future investments and the team, he has succeeded in continuing the great growth rate at a high level of sales in challenging years," said Dr. Herbert Hanselmann, adding, "We regret but respect Martin Goetzeler's decision. I would like to expressly thank him for his important contribution, his extraordinary commitment, and the close cooperation based on trust."
"It has been an exciting five years. The excellent and close cooperation with the entire dSPACE team, our customers and partners, and the shareholder family was the key to success and motivation at all times. I would like to thank everyone very much for this," said Martin Goetzeler. "After a fulfilling professional career, I would like to devote more time to my personal and family tasks and interests in the future. I wish my successor and all dSPACE employees the necessary skills, much success, and all the best for the future," said Goetzeler.
Martin Goetzeler has led the dSPACE company since March 1, 2018. Portfolio expansions in virtual and real simulation and validation to cover market and customer requirements in a timely manner, especially in automated and autonomous driving and in the software-defined vehicle were important milestones during this time. In addition to the great importance of software-in-the-loop simulation in this process, technologies such as AI and cloud are now also being used in the products. At the same time, he systematically built up structures and processes to sustainably secure the strong global growth.
About dSPACE
dSPACE is a leading provider of simulation and validation solutions worldwide for developing networked, autonomous, and electrically powered vehicles. The company's range of end-to-end solutions are used particularly by automotive manufacturers and their suppliers to test the software and hardware components in their new vehicles long before a new model is allowed on the road. Not only is dSPACE a sought-after partner in vehicle development, engineers also rely on our know-how at dSPACE when it comes to aerospace and industrial automation. Our portfolio ranges from end-to-end solutions for simulation and validation to engineering and consulting services as well as training and support. With approximately 2,200 employees worldwide, dSPACE is headquartered in Paderborn, Germany, has three project centers in Germany, and serves customers through regional dSPACE companies in the USA, the UK, France, Japan, China, Croatia, and South Korea.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230125005072/en/
Contact information
dSPACE GmbH
Bernd Schäfers-Maiwald
Vice President Corporate Communications
Tel: +49 5251 1638-714
E-Mail: bschaefers-maiwald@dspace.de
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 02:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting26.3.2026 22:30:00 EET | Press release
Spring is in full swing at the “World’s Most Famous Building.” The Empire State Building (ESB) today announced a vibrant lineup of spring events in NYC, which include special experiences, treat pop-ups, and an iconic tower lighting that captures the joy and color of the beautiful season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326216271/en/ Spring is in Full Bloom at the Empire State Building with New Festive Experiences, Sweet Treats, and Seasonal Tower Lighting “The Empire State Building Observation Deck has transformed into a celebration of the season and one of the best things to do in NYC this spring,” said Dan Rogoski, observatory general manager. “Whether it’s views beside our butterfly installation, sweet pop-ups, or a chance to spot the Easter Bunny, there is something special for every visitor.” Flutter of Color: The Empire State Building installed a brand-new photo opportunity on the 86th Floor Observati
Venture Global and Edison Announce Calcasieu Pass Arbitration Settlement26.3.2026 22:15:00 EET | Press release
Today, Venture Global and Edison jointly announced the signature of a commercial agreement for the settlement of the pending arbitration between the two companies concerning the Calcasieu Pass project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326559130/en/ Completion of the settlement is expected by the end of Q2 2026, at which point the arbitration will be terminated. The agreement fully resolves the arbitration in its entirety. As part of the settlement, Edison and Venture Global have also agreed to the delivery to Europe of additional cargoes beyond those envisaged under the long-term contract, to support gas supplies primarily to the Italian market. The first delivery is scheduled for May 2026, in Italy, at the Adriatic LNG Terminal. The agreement represents a significant step in strengthening commercial cooperation between the parties and it establishes a foundation for further future deliveries in the context
Reply Recognized as a Microsoft Frontier Partner for Enterprise AI Delivery26.3.2026 20:06:00 EET | Press release
Reply [EXM, STAR: REY] announces it has been recognized as a Microsoft Frontier Partner within the Microsoft AI Cloud Partner Program, earning the Frontier Partner Badge for demonstrating advanced capabilities in delivering AI-first solutions across Cloud & AI Platforms, AI Business Solutions, and Security. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260326965586/en/ The recognition reflects Reply’s capabilities across the Microsoft ecosystem, built through the work of its specialized companies – including Aim Reply, Business Elements Reply, Cluster Reply, Root16 Reply, Solidsoft Reply, Valorem Reply, WM Reply and Zest Reply – supporting enterprise organizations in designing, implementing, and operating AI solutions on Microsoft platforms across real-world business scenarios. The Frontier Partner badge recognizes partners that demonstrate advanced AI driven capabilities and meet rigorous badge requirements at the time of
InterSystems nimittänyt terveydenhuoltotoiminnan johtajaksi tohtori Tim Ferrisin, entisen NHS- ja Mass General ‑johtajan26.3.2026 20:00:00 EET | Tiedote
InterSystems on luovien datateknologiaratkaisujen tarjoaja, jonka ratkaisuihin on tallennettu yli miljardi terveystietotietuetta maailmanlaajuisesti. Yritys ilmoitti tänään nimittäneensä terveydenhuoltotoiminnan johtajaksi lääketieteen tohtori Tim Ferrisin. Nimityksestä ilmoitettiin samaan aikaan, kun terveydenhuoltoalan johtajat kokoontuvat vuoden 2026 HIMSS Global Health Conference & Exhibition ‑tapahtumaan. Roolissaan Ferris pääsee soveltamaan kattavaa toimialakokemustaan, kun hän ohjaa yrityksen terveydenhuoltoratkaisujen kliinistä ja strategista suuntaa maailmanlaajuisesti. Laajan kokemuksensa turvin hän toimii maailmanlaajuisten terveydenhuoltojärjestelmien ja hallitusten strategisena neuvonantajana ja suunnittelee räätälöityjä teknologiaratkaisuja, jotka perustuvat todellisiin johtotason tarpeisiin. Samalla hän edistää akateemista tutkimustaan terveysdata-arkkitehtuurista sekä johtaa julkista keskustelua tekoälyn ja hoidon tarjoamisen yhdistämisestä. Ferris tuo InterSystemsiin a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
